Document is current
Any future updates will be listed below
-
Authors
- License Information
-
More Information
Article History
Received: 8 March 2025
Accepted: 8 April 2025
First Online: 15 May 2025
Declarations
:
: DY received clinically commissioned/joint research grants from Novo Nordisk, Ono Pharmaceutical, Taisho Pharmaceutical, Terumo, and Arklay. DY also received consulting or speaker fees from Sumitomo Dainippon Pharma, Boehringer Ingelheim, Astellas Pharma, MSD, Novo Nordisk, Ono Pharmaceutical, Eli Lilly, and Takeda Pharmaceutical. HS also received speaker fees from Santen Pharmaceutical Co.,Ltd, Senjyu Pharmaceutical Co.,Ltd, Kowa company, Chugai Co.,Ltd, and Alcon Inc. YS and EI declare no conflict of interest.
